Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Tai-Hao Digital Bio-tech (THDB) is a Taiwan-based medical technology company specializing in artificial intelligence solutions for medical imaging, particularly ultrasound. The company's primary focus is on developing AI-assisted screening and diagnosis tools for breast cancer and liver diseases to improve the efficiency and accuracy of radiologists. Their flagship products, such as the BR-Assistant and BR-Viewer, utilize deep learning algorithms to detect and classify lesions in 2D and 3D ultrasound scans. THDB has successfully obtained regulatory clearances, including US FDA and Taiwan FDA approvals, for several of its software products. The company aims to integrate its AI solutions into clinical workflows globally to support early cancer detection and management. By automating the analysis of ultrasound images, THDB's technology helps reduce the operator-dependent variability inherent in traditional ultrasound examinations.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on THDB.